TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17622343
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (agalsidase alfa and beta)
Study: 9475315
Drug: Prenatal steroid
Normalized name: Ardisia crenata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal steroid treatment in preterm babies
Study: 7947529
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 800 micrograms misoprostol
Study: 7947529
Drug: Sequential regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential regimen
Study: 3328682
Drug: Ketanserin 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 0.5 mg kg‐1
Study: 31340751
Drug: Probiotics (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (30 billion CFU of a mixture of six viable strains) taken orally twice daily for six months
Study: 26903303
Drug: Powder vehicle
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder vehicle compound of vitamin D (100,000 IU cholecalciferol)
Study: 26903303
Drug: Powder vehicle
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder vehicle compound of vitamin D
Study: 26903303
Drug: Oil vehicle
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oil vehicle compound of vitamin D (100,000 IU cholecalciferol)
Study: 25784512
Drug: Bococizumab 150
Normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bococizumab 150 mg Q14 days
Study: 25784512
Drug: Bococizumab 300
Normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bococizumab 300 mg Q28 days
Study: 19685930
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with S-1 after D2 resection
Study: 19685930
Drug: Oral fluoropyrimidines
Normalized name: 5-Fluoropyrimidine-2,4-dione
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral fluoropyrimidines (capecitabine)
Study: 11151453
Drug: Trastuzumab in
Normalized name: trastuzumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab in combination with chemotherapy
Study: 14749694
Drug: Fluvoxamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (50 mg for 2 days and 100 mg for 4 days)
Study: 7514513
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of human growth hormone (Norditropin) in the abdomen
Study: 7514513
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of human growth hormone (Norditropin) in the thigh
Study: 3497572
Drug: Calcium (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1000 mg/d) and ergocalciferol (20 micrograms/d) supplementation for 6 months
Study: 11145360
Drug: Fluoride or
Normalized name: sodium fluoride Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride or chlorhexidine varnish treatment
Study: 8598866
Drug: Anticoagulant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant therapy (intravenous heparin, phenprocoumon, and aspirin)
Study: 8598866
Drug: Antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy (ticlopidine plus aspirin)
Study: 1412114
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment at 31 degrees C
Study: 26945662
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg Finasteride daily for 4 weeks before TURP
Study: 6324526
Drug: Photocoagulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photocoagulation therapy (mild treatment with panretinal, focal or both techniques using short‐pulse, small‐spot xenon arc or argon laser methods)
Study: 26812052
Drug: Prednisolone 5
Normalized name: prednisolone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 5 mg per day
Study: 26812052
Drug: Prednisolone 5
Normalized name: prednisolone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 5 mg per day (females)
Study: 24445121
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied heat at 42°C for 30 seconds daily with allantoin lotion formulation
Study: 24445121
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied heat at 42°C for 30 seconds daily with allantoin gel formulation
Study: 404621
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin injection
Study: 15721015
Drug: Roxithromycin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin (400 mg daily for 4 weeks)
Study: 31167060
Drug: Macrolide treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macrolide treatment
Study: 3103424
Drug: Red pepper
Normalized name: Red pepper
DrugBank: Red pepper (DB14759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red pepper (0.1-1.5 g)
Study: 3103424
Drug: Black pepper
Normalized name: Black Pepper
DrugBank: Black pepper (DB10557)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black pepper (1.5 g)
Study: 30253174
Drug: Istradefylline 40
Normalized name: istradefylline 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Istradefylline 40 mg
Study: 18372428
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of metformin twice daily for 5 days followed by 850 mg twice daily for 5 days
Study: 23134162
Drug: Intravenous catheter
Normalized name: intravenous catheter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous catheter
Study: 6222700
Drug: Intralesional corticosteroids
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional corticosteroids (Triamcinolone acetonide at 0.63 mg/mL)
Study: 6222700
Drug: Intralesional corticosteroids
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional corticosteroids (Betamethasone phosphate at 3.0, 1.5, and 0.75 mg/mL)
Study: 19446324
Drug: Daily interruption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily interruption of sedation with therapy as ordered by the primary care team
Study: 6856226
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 0.5% bupivacaine, dilute epinephrine, and methylergonovine maleate (randomized drug regimens)
Study: 23550422
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg and extended release nicotinic acid 1G
Study: 18381377
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of bone marrow mononuclear cells (BMC)
Study: 29923955
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (control group)
Study: 17027571
Drug: Rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (4 mg/day)
Study: 12792352
Drug: Continued treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued treatment with stavudine and/or protease inhibitor
Study: 1515247
Drug: Alizapride 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alizapride 2.5 mg/kg four times daily on days 2-5 plus dexamethasone as in group C
Study: 1515247
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg twice daily on days 2 and 3, then 4 mg twice daily on days 4 and 5
Study: 30529387
Drug: Sorafenib +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib + concurrent transarterial chemoembolization (cTACE)
Study: 8842603
Drug: Glimepiride 8
Normalized name: glimepiride 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 8 mg
Study: 11572297
Drug: Compomer/hybrid combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compomer/hybrid combination
Study: 11572297
Drug: Flowable/hybrid combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flowable/hybrid combination
Study: 7933494
Drug: Hypertonic lactated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic lactated Ringer's solution (HLS) with sodium of 213 mEq.l‐1
Study: 7933494
Drug: Regular lactated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular lactated Ringer's solution (control)
Study: 3230151
Drug: Immediate-release verapamil
Normalized name: verapamil Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release verapamil (80 to 120 mg three times a day)
Study: 3230151
Drug: Sustained-release verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release verapamil (240 mg daily)
Study: 30630788
Drug: Routine western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine western drug therapy
Study: 31416769
Drug: Riociguat (0.5-2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riociguat (0.5-2.5 mg three times daily)
Study: 23902840
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide 320 µg/day plus formoterol 9 µg/day
Study: 20196184
Drug: Long-term lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-term lithium treatment
Study: 14608586
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of different strategies in a multi-level approach
Study: 11307438
Drug: One-visit root
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-visit root canal treatment without calcium hydroxide dressing.
Study: 9305334
Drug: Gabapentin 3,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 3,600 mg/d
Study: 3830245
Drug: Caffeine (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (oral, 5.83 mg X kg‐1 lean body weight)
Study: 31739991
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg/day and Bevacizumab 10 mg/kg every 14 days on a 28-day cycle
Study: 17256446
Drug: Erdosteine with
Normalized name: erdosteine
DrugBank: Erdosteine (DB05057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erdosteine with amoxicillin
Study: 17256446
Drug: Amoxicillin-placebo combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-placebo combination
Study: 26422093
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg (for children > 20 kg)
Study: 17327934
Drug: Esomeprazole (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (all doses)
Study: 23274592
Drug: Astaxanthin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astaxanthin (20 mg per day for 4 weeks)
Study: 21482348
Drug: Low-molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular weight heparin (LMWH) dalteparin 5000 IU once daily
Study: 21482348
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) 5000 IU subcutaneous injection
Study: 15019387
Drug: Superomedial retrobulbar
Normalized name: bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Superomedial retrobulbar injection
Study: 21215828
Drug: DTaP and
Normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP and IPV vaccines (separate administration)
Study: 17958944
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa (once-weekly)
Study: 12484708
Drug: Echinacea (1-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echinacea (1-g doses six times on the first day and three times on each subsequent day for a maximum of 10 days)
Study: 9932945
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of regular-release levodopa (rr-L-dopa) and sustained-release levodopa (sr-L-dopa)
Study: 7474027
Drug: Daily acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily acupuncture in three auricular sites plus one body site (LI-4)
Study: 375733
Drug: Topical therapy
Normalized name: Diclosaicin 1.5%-0.025% Topical Therapy Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical therapy with Nonoxynol 9
Study: 30836166
Drug: 78 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 78 Gy in 39 fractions of photon radiation therapy
Study: 30836166
Drug: 70 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 Gy in 35 fractions of photon radiation therapy
Study: 24285599
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g fish oil/day (540 mg eicosapentaenoic acid + 360 mg docosahexaenoic acid)
Study: 26251920
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g soy oil/day (placebo)
Study: 22990031
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate supplementation (1000 mg Ca/d, 5 d/wk) for 12 months
Study: 20149038
Drug: Acute oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute oral hydration
Study: 17316154
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa administered weekly, every 2 weeks, and every 3 weeks
Study: 17316154
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa (weight-based and fixed dosing)
Study: 17316154
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa at extended dosing intervals of at least 3 weeks
Study: 11579362
Drug: Candesartan and
Normalized name: candesartan and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan and Enalapril combination
Study: 9833602
Drug: Frusemide administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide administered at a constant-rate intravenous infusion for 10 min
Study: 9833602
Drug: Frusemide administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide administered at a constant-rate intravenous infusion for 30 min
Study: 30231173
Drug: 1% HA
Normalized name: TheraSeal 1% Hand Protection Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% HA gel
Study: 20693270
Drug: SCH351125 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH351125 (oral CCR5 inhibitor)
Study: 10648312
Drug: Dimenhydrinate suppositories
Normalized name: Dimenhydrinate
DrugBank: Dimenhydrinate (DB00985)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dimenhydrinate suppositories
Study: 8382708
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg tirilazad mesylate
Study: 8382708
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg tirilazad mesylate
Study: 8382708
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg tirilazad mesylate
Study: 8382708
Drug: 2.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg/kg tirilazad mesylate
Study: 2876337
Drug: Aspirin sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin sensitivity
Study: 30594335
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy including neurodynamic techniques (MT).
Study: 30594335
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG; without therapy).
Study: 23890962
Drug: Endoscopic thyroidectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic thyroidectomy using the oral vestibular approach (ETOVA)
Study: 12492610
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (8 mg once a day)
Study: 3028456
Drug: Frusemide 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide 80 mg
Study: 22822928
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of flurbiprofen (40 mg administered twice at 16 and 2 hours before surgery)
Study: 15117238
Drug: 0.2% GTN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% GTN gel twice a day for a minimum of 6 weeks
Study: 11284826
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of ondansetron
Study: 3285630
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of etretinate and PUVA
Study: 29607842
Drug: Platelet-rich fibrin
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich fibrin gel
Study: 21075366
Drug: Adjusted thermal
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted thermal dose based on ovarian volume (60 J/cm³ of ovarian tissue)
Study: 21075366
Drug: Fixed thermal
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed thermal dosage (600 J per ovary)
Study: 7701222
Drug: Caldwell-Luc (C-L)
Normalized name: L-deprenyl-D2 C-11
DrugBank: L-deprenyl-D2 C-11 (DB12650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caldwell-Luc (C-L) procedure
Study: 1619991
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) administration (12 IU/d subcutaneously)
Study: 29595123
Drug: Salbutamol 4
Normalized name: Salbutamol 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol 4 mg
Study: 30382016
Drug: Adjunctive rifampicin
Normalized name: rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive rifampicin (600-900 mg/day, oral or intravenous) for 14 days
Study: 28078869
Drug: High energy
Normalized name: High energy formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: High energy laser therapy (HELT) at 650 nm
Study: 11437176
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (25 mg/d)
Study: 28304313
Drug: Group music
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group music therapy offered once weekly for 16 weeks
Study: 28304313
Drug: Group recreational
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group recreational therapy
Study: 25887806
Drug: Triple Antibiotic
Normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple Antibiotic Paste (TAP) at 1000 mg/mL
Study: 25887806
Drug: Triple Antibiotic
Normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple Antibiotic Paste (TAP) at 0.5 mg/mL
Study: 25887806
Drug: Double Antibiotic
Normalized name: Double Antibiotic
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double Antibiotic Paste (DAP) at 0.5 mg/mL
Study: 24195278
Drug: Chloramine T
Normalized name: chloramine t
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloramine T (2 mg/l)
Study: 24195278
Drug: Peracetic acid
Normalized name: PERACETIC ACID
DrugBank: Peracetic acid (DB14556)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peracetic acid (45 microl/l)
Study: 15894097
Drug: Tamoxifen (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (5 years) following anthracycline-based chemotherapy
Study: 15894097
Drug: Anthracycline-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracycline-based chemotherapy followed by tamoxifen
Study: 7840379
Drug: Nutrient hepatic
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrient hepatic blood flow > 325 mL/min
Study: 623129
Drug: Other antibiotics
Normalized name: Other antibiotics for topical use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antibiotics due to specific indications or counterindications
Study: 25631485
Drug: 0.1% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% sodium hyaluronate ophthalmic solution (HA)
Study: 23883675
Drug: Ad libitum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad libitum high-fiber, low-fat diet and daily exercise (2-2.5 h)
Study: 15089811
Drug: FTY720 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTY720 (1 mg oral dose) under fasting conditions
Study: 15089811
Drug: FTY720 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTY720 (1 mg oral dose) after a high fat meal
Study: 11575286
Drug: Leuprolide and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide and pamidronate (60 mg intravenously every 12 weeks)
Study: 3754233
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg bd
Study: 9600792
Drug: Ibandronate treatment
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate treatment
Study: 20716738
Drug: Gentamicin-collagen sponge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin-collagen sponge (2 sponges, total gentamicin of 260 mg)
Study: 18085275
Drug: LDIH (60-minute
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDIH (60-minute daily exposures to normobaric 12% O2)